46 results on '"Jose, Vinu"'
Search Results
2. Microtubule targeting agents influence the clinical benefit of immune response in early breast cancer.
Catalog
Books, media, physical & digital resources
3. Gene expression data from the FinHER adjuvant breast cancer trial comparing microtubule targeting agents
4. Pooled breast cancer gene expression dataset with detailed treatment regimen characterization
5. Regulatory Approval Scenario of Biosimilars in Pediatric Patients in the United States and European Union
6. Single-Dose Pharmacokinetics, Pharmacodynamics and Immunogenicity, and Multiple-Dose Immunogenicity of INTP5 (Pegfilgrastim Biosimilar) Versus Reference Pegfilgrastim in Healthy Subjects
7. A randomized, double-blind, parallel-group, single‑dose, pharmacokinetic bioequivalence study of INTP24 and bevacizumab in healthy adult men
8. Safety and efficacy of Razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study
9. An update on the animal studies conducted for biosimilar approvals – Regulatory requirement vs actual scenario
10. Pharmacokinetic and pharmacodynamic bioequivalence study of a pegfilgrastim biosimilar INTP5 in healthy subjects
11. Impact of treatments on the clinical value of immune response in breast cancer: an insilico analysis
12. Denosumab biosimilar in postmenopausal osteoporotic women: A randomized, assessor-blind, active-controlled clinical trial
13. Bevacizumab for eye diseases - Legal, regulatory, and ethical overview
14. Causes of DMARD withdrawal following ADR within 6 months of initiation among Indian rheumatoid arthritis patients
15. A review of use errors reported in human factor validation studies of biological combination products
16. Denosumab biosimilar in postmenopausal osteoporotic women: A randomized, assessor-blind, active-controlled clinical trial
17. Single-Dose Pharmacokinetics, Pharmacodynamics and Immunogenicity, and Multiple-Dose Immunogenicity of INTP5 (Pegfilgrastim Biosimilar) Versus Reference Pegfilgrastim in Healthy Subjects
18. Abstract 3853: The anti-tumor immune responses by active and quiescent tertiary lymphoid structures to breast cancer
19. FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer
20. Insights into human factor studies conducted for US FDA-approved biological combination products
21. Pharmacokinetics and Pharmacodynamics of Insulin Tregopil in Relation to Premeal Dosing Time, Between Meal Interval, and Meal Composition in Patients With Type 2 Diabetes Mellitus
22. Impact of Insulin Tregopil and Its Permeation Enhancer on Pharmacokinetics of Metformin in Healthy Volunteers: Randomized, Open‐Label, Placebo‐Controlled, Crossover Study
23. FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer
24. Feasibility of developing reliable gene expression modules from FFPE derived RNA profiled on Affymetrix arrays
25. Pharmacokinetics and Pharmacodynamics of Insulin Tregopil in Relation to Premeal Dosing Time, Between Meal Interval, and Meal Composition in Patients With Type 2 Diabetes Mellitus.
26. Feasibility of developing reliable gene expression modules from FFPE derived RNA profiled on Affymetrix arrays
27. Pharmacodynamic Effect of Novel Oral Insulin Tregopil in Relation to Meal Composition in Type 2 Diabetes Mellitus Patients
28. Dosing Time of Insulin Tregopil, a Novel Oral Insulin, in Type 2 Diabetes Mellitus Patients and Its Pharmacodynamic Effect
29. Changing trend in the use of antimicrobials over ten years in a tertiary care hospital
30. CD73 promotes resistance to HER2/ErbB2 antibody therapy
31. Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers.
32. Biology of breast cancer during pregnancy using genomic profiling.
33. Evaluation of PI3K-pathway–activation status in matched primary (P) and metastatic (M) ER+/HER2- breast cancer (BC) lesions according to PIK3CA-mutation status.
34. Tumor infiltrating lymphocytes is prognostic and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.
35. Evaluation of PI3K-pathway–activation status in matched primary (P) and metastatic (M) ER+/HER2- breast cancer (BC) lesions according to PIK3CA-mutation status.
36. Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC).
37. Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC)
38. Effect of sample preservation method and transportation duration on tumor gene expression profiling in breast cancer.
39. Effect of sample preservation method and transportation duration on tumor gene expression profiling in breast cancer
40. Changing trend in the use of antimicrobials over ten years in a tertiary care hospital
41. Causes of DMARD withdrawal following ADR within 6 months of initiation among Indian rheumatoid arthritis patients
42. Biology of breast cancer during pregnancy using genomic profiling.
43. Treatment failure with disease-modifying antirheumatic drugs in rheumatoid arthritis patients.
44. Changing chronobiology of cardiovascular outcome following prophylaxis.
45. Antiepileptic TDM pattern at a tertiary care hospital in India.
46. Effect of potassium channel modulators on toxicity of Cleistanthus collinus.
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.